Welcome to our dedicated page for HeartBeam SEC filings (Ticker: BEAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartBeam, Inc. filings document material events for a Nasdaq-listed medical technology issuer with common stock under BEAT and warrants under BEATW. Its 8-K disclosures cover underwriting agreements and common-stock offering terms, emerging growth company status, and FDA-related correspondence for its 12-Lead ECG Synthesis Software.
These records also identify capital-structure changes and formal event disclosures tied to commercialization and regulatory development of HeartBeam's 3D ECG technology.
HeartBeam, Inc. director Richard Ferrari reported an open-market purchase of 62,500 shares of common stock at $0.80 per share. Following this buy, he directly holds 291,636 shares. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, which priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. President Robert Paul Eno reported an open-market purchase of common stock. On April 16, 2026, he bought 12,500 shares at $0.80 per share, increasing his direct holdings to 36,742 shares.
The purchased shares were acquired in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. His reported holdings include 23,333 RSUs that have vested as referenced in a prior Form 4 filing.
HeartBeam, Inc. director Marga Ortigas-Wedekind purchased 25,000 shares of Common Stock on April 16, 2026 in an open-market transaction at $0.80 per share, bringing her direct holdings to 137,293 shares.
According to a footnote, these shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock. Titan Partners, a division of American Capital Partners, acted as the sole bookrunner for this offering, which priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. director-associated entities acquired 750,000 shares of common stock at $0.80 per share in an underwritten public offering of 12,500,000 shares. The purchase was an open-market style transaction tied to the offering that priced on April 14, 2026 and closed on April 16, 2026.
The shares are held by Strome Mezzanine Fund II, LP, the Mark E. Strome Living Trust and Strome Dynasty, LLC. Following this transaction, entities associated with director Mark E. Strome hold 3,650,000 shares of HeartBeam common stock indirectly. Mr. Strome has voting and disposal authority but disclaims beneficial ownership beyond his pecuniary interest.
HeartBeam, Inc. entered an underwriting agreement with Titan Partners Group for an underwritten public offering of 12,500,000 shares of common stock at a public price of $0.80 per share, raising approximately $10.0 million in gross proceeds upon closing.
The underwriter will purchase shares at $0.744 per share and holds a 30‑day option to buy up to 1,875,000 additional shares to cover over‑allotments. HeartBeam will also issue underwriter warrants equal to 5% of the total shares sold, exercisable immediately for five years.
The company and its officers and directors agreed to a 75‑day lock‑up on specified securities. Net proceeds are intended to support commercialization of its FDA‑cleared 12‑lead synthesized ECG system, development of its extended‑wear patch and heart attack detection initiatives, enhancement of AI capabilities, and working capital and general corporate purposes.
HeartBeam, Inc. is offering 12,500,000 shares of common stock at $0.80 per share in a firm commitment underwritten offering, with net proceeds estimated at approximately $8.9 million. The underwriter has a 30-day option to purchase up to 1,875,000 additional shares. The company will also issue underwriter warrants to purchase up to 625,000 shares at an exercise price of $0.92 (115% of the offering price). Proceeds are intended to fund commercialization of the FDA-cleared 12-lead synthesized ECG system, development of a 12-lead patch and heart attack detection efforts, AI capabilities, and general corporate purposes. Trading symbol is BEAT on the Nasdaq Capital Market and the last reported sale price shown in the supplement was $1.20 per share.
HeartBeam, Inc. is offering [●] shares of Common Stock and, in lieu of shares that would push a purchaser above a 4.99% ownership cap, pre-funded warrants exercisable for one share (exercise price $0.001). The offering is underwritten on a firm commitment basis and includes an up to 30-day, up-to-30% over-allotment option. The company holds two FDA clearances for its cable-free, synthesized 12-lead ECG system (arrhythmia assessment) and recently announced a commercial LOI with ClearCardio, enrollment in the ALIGN-ACS ER study, and a working prototype of a 12L patch. Management and auditors have expressed substantial doubt about the company’s ability to continue as a going concern.
HeartBeam, Inc. director Marga Ortigas-Wedekind received a grant of stock options representing the right to buy 44,827 shares of common stock at an exercise price of $1.43 per share. This is a compensation-related award, not an open-market share purchase or sale.
According to the grant terms, one half of the options, covering 22,413.5 underlying shares, will vest on March 31, 2026, and the remaining half will vest on June 30, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and expire on January 1, 2036, giving the director a long-term incentive tied to the company’s share performance.
HeartBeam, Inc. director Richard Ferrari reported an equity award of 50,000 shares of common stock in the form of restricted stock units. The grant was made on February 9, 2026 and increased his directly held position to 229,136 shares.
According to the award terms, one half of the RSU shares will vest on March 31, 2026, and the remaining half will vest on June 30, 2026, based on a vesting commencement date of January 1, 2026. The RSUs were issued under HeartBeam’s 2022 Equity Incentive Plan and carry no cash exercise price.
HeartBeam, Inc. reported that major shareholder Mark E. Strome received a grant of stock options to acquire 41,380 shares of common stock at an exercise price of $1.43 per share. Half of these options vest on March 31, 2026 and the remaining half on June 30, 2026, with an expiration date of January 1, 2036. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent compensation rather than an open-market purchase or sale.